A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 21, 2017

Primary Completion Date

July 16, 2024

Study Completion Date

July 16, 2024

Conditions
Hemophilia A
Interventions
BIOLOGICAL

SB-525 (PF-07055480)

Single dose of investigational product SB-525 (PF-07055480)

Trial Locations (22)

15213

Hemophilia Center of Western PA, Pittsburgh

UPMC Montefiore Clinical and Translational Research Center, Pittsburgh

UPMC, Investigational Drug Service, Pittsburgh

30322

Emory University School of Medicine, Atlanta

33136

University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center, Miami

33612

USF Health Morsani Center For Advanced Healthcare, Tampa

37232

Vanderbilt Hemostasis Treatment Clinic, Nashville

Vanderbilt Hemostasis-Thrombosis Clinic, Nashville

72202

Arkansas Children's Hospital, Little Rock

91010

City of Hope Medical Center, Duarte

94143

University of California, San Francisco - Outpatient Hematology Clinic, San Francisco

University of California, San Francisco -Moffitt Hospital, San Francisco

95817

Midtown Ambulatory Care Center, Sacramento

UC Davis Ambulatory Care Clinic, Sacramento

UC Davis Comprehensive Cancer Center, Sacramento

UC Davis CTSC Clinical Research Center, Sacramento

UC Davis Hemophilia Treatment Center, Sacramento

UC Davis Investigational Drug Services Pharmacy, Sacramento

UC Davis Medical Center, Sacramento

98101

Washington Institute for Coagulation, Seattle

94143-0622

University of California, San Francisco - Investigational Drug Service (IDS) Pharmacy, San Francisco

37212-8646

Vanderbilt University Medical Center Clinical Research Center, Nashville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY